peginterferon plus ribavirin and glutamine therapy against chronic hepatitis C

peginterferon plus ribavirin and glutamine therapy against chronic hepatitis C - IFN + glutamine therapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003865

Enrollment

Registered

2010-08-01

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

peginterferon plus ribavirin and oral administration of glutamine peginterferon plus ribavirin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: genotype 1b and high viral load (greater than 5.0LogIU/mL)

Exclusion criteria

Exclusion criteria: liver cirrhosis autoimmune hepatitis primary biliary cirrhosis malignancy depression drug abuse pregnant or lactating woman

Design outcomes

Primary

Measure	Time frame
Sustained virological response or non-response	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactYoshimichi Haruna

Osaka Prefectural General Medical Center Department of Gastroenterology and Hepatology

apple-123-grape@ab.auone-net.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026